TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03182881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lymphatic Drainage
Description: It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
Study: NCT05007626

Intervention type: OTHER
Intervention: axial length and refractive error
Description: Comparing the correlation between heterophoria and refraction, even after age adjustment.
Study: NCT03602703

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry and Western Blot analysis
Description: Diagnostic tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry and Western Blot analysis
Description: Diagnostic tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry and Western Blot analysis
Description: Diagnostic tests
Study: NCT00613392

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: powdered antioxidant
Description: one vial mixed with water every day orally or through enteral tube

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: powdered cornstarch placebo
Description: one vial mix with water and administer orally or via enteral tube
Study: NCT00928850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms
Description: Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms
Description: Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms
Description: Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms
Description: Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
Study: NCT05221697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESAGE CARE
Description: Participants in this arm will be followed by HCA and might benefit from Nurse health interventions
Study: NCT04837287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching Exercise for 10 Seconds
Description: The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 10 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching Exercise for 30 Seconds
Description: The participants were asked to do a static stretching exercise for the Hamstring and Gracilis muscles for 30 seconds. The participants were asked to continue for 8 weeks, 3 days a week, 3 times a day - 10 repetitions.
Study: NCT02589847

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBX2660
Description: suspension of intestinal microbes

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care Antibiotics
Description: Standard of Care Antibiotics
Study: NCT02834858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT03570203

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Sodium
Description: Measurement of serum sodium.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Sodium
Description: Measurement of serum sodium.
Study: NCT01602705

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback of Performance
Description: Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback of Performance + Health Psychology Informed Intervention
Description: Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
Study: NCT03709147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin 1500 mg/day up to disease progression or unacceptable toxicity Every-21-days, 5-day Fasting-mimicking diet (FMD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous cisplatin, administered at a dosage of 75 mg/mq every three weeks for a maximim of 4 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at an area-under-the-curve (AUC) of 5, administered intravenously every-three weeks for a maximum of 4 consecutive cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, administered intravenously at the dose of 500 mg/mq every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet
Description: 5-day fasting-mimicking diet regimen, consisting of 700 KCal on day 1, 300 KCal on days 2-4, and 450 KCal on day 5, to be repeated every three weeks up to a maximum of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab, administered intravenously at the flat dose of 200 mg every-three weeks up to a maximum of 4 cycles in combination with platinum compounds, and then as a maintenance treatments in patients not undergoing disease progression after the first 4 chemotherapy cycles
Study: NCT02585713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00178217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
Study: NCT03845244

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow reduction first
Description: -10L/min q 1hr

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FiO2 reduction first
Description: - 0.1 q 1hr

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous (flow and FiO2) reduction
Description: -10L/min and -0.1 q 1hr
Study: NCT00361803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: topotecan
Study: NCT01050322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib Vinorelbine
Description: The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib Capecitabine
Description: The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Lapatinib
Description: The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
Study: NCT04687826

Intervention type: OTHER
Intervention: Goal directed fluid therapy
Description: Patients in 2015 got intraoperative fluid therapy in goal directed fluid therapy technique.

Intervention type: OTHER
Intervention: Liberal fluid therapy
Description: Patients in 2017 got liberal intraoperative fluid therapy influenced by their anaesthesiologist.
Study: NCT01860716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03492879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIT Technology
Description: Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIT Technology
Description: Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIT Technology
Description: Electrical Impedance Technology is a non-invasive imaging method who is being tested for evaluation of liver fibrosis stage
Study: NCT01816178

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: communication training
Description: Participants were instructed in the use of a voices output communication aid.
Study: NCT01648920

Intervention type: DEVICE
Intervention: NIOX MINO® Instrument (09-1100)
Description: The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
Study: NCT01698944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
Study: NCT00090870

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Peg-Intron 1ug/kg Subcutaneous on day 1 and day 8 of each cycle. Each cycle is 21 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF 250 ug/m2 subcutaneously daily from days 1-10 or each 21 day Peg-Intron cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: 200mg daily by mouth
Study: NCT00613379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: 10 mg/kg PRO 140, one IV dose (N=10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140
Description: 5 mg/kg PRO 140, one IV dose (N=10)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PBO, one IV dose (N=10)
Study: NCT00990509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain MRI with and without contrast
Description: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~* Baseline~* 48 hours after enrollment(approximately Day 3)~* 96 hours after drug treatment begins (approximately Day 5)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Brain MRI with and without contrast
Description: All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.~MRIs will be with and without contrast will be performed at:~* Baseline~* 48 hours after enrollment(approximately Day 3)~* 96 hours after drug treatment begins (approximately Day 5)
Study: NCT01639248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENMD-2076
Description: 250 mg per day in oral capsules in 28 day continuous cycles
Study: NCT00685867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid molecular MRSA test
Description: PCR-based rapid screening for MRSA carriage

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hand hygiene promotion
Description: * Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance~* Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)~* Isolation precautions according to the hospitals' capacity and strategy~* Additional basic infection control interventions (if necessary)
Study: NCT03608813

Intervention type: OTHER
Intervention: Serum Metabolomics profiling
Description: Untargeted serum metabolomics profiling

Intervention type: OTHER
Intervention: Serum Metabolomics profiling
Description: Untargeted serum metabolomics profiling
Study: NCT01078142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus, Rituximab, Bendamustin
Description: Phase I:~Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)
Study: NCT01385540

Intervention type: BEHAVIORAL
Intervention: Task-Based Functional Magnetic Resonance Imaging (fMRI)
Description: Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
Study: NCT02302040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIM2ACT
Description: AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-guided
Description: Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
Study: NCT01939223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
Study: NCT02666001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine and Norbuprenorphine
Description: Buprenorphine and Norbuprenorphine
Study: NCT00985972

Intervention type: BEHAVIORAL
Intervention: Physical Activity and Nutrition Education
Description: School-based interventions involving Physical Activity or/and Nutrition Education.

Intervention type: BEHAVIORAL
Intervention: Physical Activity and Nutrition Education
Description: School-based interventions involving Physical Activity or/and Nutrition Education.
Study: NCT02497404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Description: Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irradiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,~-8 and -7. This will be administered on an outpatient basis if possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fludarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 30 mg subcutaneously on Days -4 and -2 for unrelated donors, and Day -2 for related donors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Total Body Irradiation (TBI) will be given at 2 doses of 200 cGy each on one day of the conditioning regimen (between days -6 and -3).
Study: NCT02308228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training
Description: Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Progressive Resistance Training
Description: Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will be randomized to receive metformin in conjunction with their strength training program.
Study: NCT00298883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Myfortic 360mg PO BID for six weeks
Study: NCT02421419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: adreno-cortical steroid anti-inflammatory drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: adreno-cortical steroid anti-inflammatory drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone Sodium Phosphate
Description: adreno-cortical steroid anti-inflammatory drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: a local anesthetic agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Chloride
Description: Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment